Publications by authors named "Hassan ElKayal"
Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal (SRF) and intraretinal fluid associated with circumscribed choroidal haemangiomas (CCH).
Methods: This was a retrospective review of all patients treated with at least 3 bevacizumab injections for CCH-associated SRF between May 2020 and August 2023 in Moorfields eye hospital. Outcome measures included change in best corrected visual acuity (BCVA), change in patient reported symptoms, change in SRF and change in central subfield thickness (CSFT).
Purpose: To compare the efficacy of pars plana vitrectomy (PPV) versus intravitreal injection (IVI) of ranibizumab (RBZ) in the treatment of diabetic macular edema (DME) associated with vitreomacular interface abnormalities (VMIA).
Methods: The records of patients presenting with DME and VMIA throughout 2016 to 2018 were retrospectively analyzed. The patients were divided into 2 groups: group I received IVIs of RBZ and group II underwent PPV with internal limiting membrane peeling.
Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ophthalmic Surg Lasers Imaging Retina
March 2017
Background And Objectives: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA).
Patients And Methods: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept.